Starton Therapeutics Signs Clinical Trial Agreement with the Stanford School of Medicine to Evaluate STAR-LLD Combo with Novel CAR-T for Multiple Myeloma
“We are excited to collaborate with Stanford Medicine and advance the evaluation of STAR-LLD,” said Pedro Lichtinger, Chairman and CEO. “This agreement represents an important step in our strategy, as we believe this combination has the potential to improve CAR-T cell expansion and persistence, while minimizing the known toxicity of immunomodulatory imide drugs (IMiD).”
Share:
More News
“We’ve already seen what subcutaneous amivantamab may offer patients with head and neck cancer after their disease has progressed. Now, we see the potential impact of using this approach earlier in recurrent or metastatic disease,” said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson. “Our
“Meaningful progress has been made in the treatment of pancreatic cancer and we are proud that Tumor Treating Fields therapy is one of the new options available to patients. However, advanced pancreatic cancer remains one of the most difficult cancers to treat,” said Uri Weinberg, MD, PhD, Chief Medical and
“We see anal cancer as the starting point for building a pelareorep plus checkpoint inhibitor platform across HPV-driven cancers,” said Jared Kelly, Chief Executive Officer of Oncolytics. “Our survival data and recent FDA regulatory clarity give us a path to pursue registration in anal cancer while expanding into other HPV-associated
“Multiple myeloma is a chronic blood cancer that can reshape a person’s life. Patients deserve therapeutic options that are not only effective, but also support the realities of when, where and how they receive treatment,” said Daejin Abidoye, M.D., vice president and therapeutic area head, oncology, solid tumor and hematology,